source
- Merck halts $2.7 billion BTK inhibitor program after negative phase 3 dataMerck announced it is discontinuing its BTK inhibitor nemtabrutinib program, ending three phase 3 trials in chronic lymphocytic leukemia and small lymphocytic lymphoma. The decision follows a reco…
- Quanterix CEO Everett Cunningham resigns after ten months, interim leader appointedQuanterix announced that Everett Cunningham will leave his role as president and chief executive officer after serving less than a year. The company said he will step down to pursue another opportu…